ABL1 is an inclusion eligibility criterion in 8 clinical trials for juvenile myelomonocytic leukemia, of which 3 are open and 5 are closed. Of the trials that contain ABL1 status and juvenile myelomonocytic leukemia as inclusion criteria, 2 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (1 open), 1 is phase 3 (1 open), and 1 is no phase specified (0 open) [3].

AFF1 is an inclusion eligibility criterion in 7 clinical trials for juvenile myelomonocytic leukemia, of which 3 are open and 4 are closed. Of the trials that contain AFF1 status and juvenile myelomonocytic leukemia as inclusion criteria, 2 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (1 open), and 1 is phase 3 (1 open) [3].

BCR is an inclusion eligibility criterion in 8 clinical trials for juvenile myelomonocytic leukemia, of which 3 are open and 5 are closed. Of the trials that contain BCR status and juvenile myelomonocytic leukemia as inclusion criteria, 2 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (1 open), 1 is phase 3 (1 open), and 1 is no phase specified (0 open) [3].

CBFA2T3 is an inclusion eligibility criterion in 1 clinical trial for juvenile myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains CBFA2T3 status and juvenile myelomonocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

CBFB is an inclusion eligibility criterion in 1 clinical trial for juvenile myelomonocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains CBFB status and juvenile myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

CBL is altered in 18.18% of juvenile myelomonocytic leukemia patients [2].

CBL is an inclusion eligibility criterion in 1 clinical trial for juvenile myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains CBL status and juvenile myelomonocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

CREBBP is altered in 10.0% of juvenile myelomonocytic leukemia patients [2].

CREBBP is an inclusion eligibility criterion in 1 clinical trial for juvenile myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains CREBBP status and juvenile myelomonocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

DEK is an inclusion eligibility criterion in 7 clinical trials for juvenile myelomonocytic leukemia, of which 3 are open and 4 are closed. Of the trials that contain DEK status and juvenile myelomonocytic leukemia as inclusion criteria, 2 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (1 open), and 1 is phase 3 (1 open) [3].

ELL is an inclusion eligibility criterion in 7 clinical trials for juvenile myelomonocytic leukemia, of which 3 are open and 4 are closed. Of the trials that contain ELL status and juvenile myelomonocytic leukemia as inclusion criteria, 2 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (1 open), and 1 is phase 3 (1 open) [3].

ETV6 is an inclusion eligibility criterion in 1 clinical trial for juvenile myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains ETV6 status and juvenile myelomonocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT3 is an inclusion eligibility criterion in 8 clinical trials for juvenile myelomonocytic leukemia, of which 3 are open and 5 are closed. Of the trials that contain FLT3 status and juvenile myelomonocytic leukemia as inclusion criteria, 2 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 4 are phase 2 (1 open), and 1 is phase 3 (1 open) [3].

GLIS2 is an inclusion eligibility criterion in 1 clinical trial for juvenile myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains GLIS2 status and juvenile myelomonocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

HOXA9 is an inclusion eligibility criterion in 1 clinical trial for juvenile myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains HOXA9 status and juvenile myelomonocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

HRAS is an inclusion eligibility criterion in 1 clinical trial for juvenile myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and juvenile myelomonocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

KAT6A is an inclusion eligibility criterion in 1 clinical trial for juvenile myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains KAT6A status and juvenile myelomonocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

KDM5A is an inclusion eligibility criterion in 1 clinical trial for juvenile myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains KDM5A status and juvenile myelomonocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

KIT is an inclusion eligibility criterion in 1 clinical trial for juvenile myelomonocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains KIT status and juvenile myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

KMT2A is an inclusion eligibility criterion in 7 clinical trials for juvenile myelomonocytic leukemia, of which 3 are open and 4 are closed. Of the trials that contain KMT2A status and juvenile myelomonocytic leukemia as inclusion criteria, 2 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (1 open), and 1 is phase 3 (1 open) [3].

KRAS is altered in 9.09% of juvenile myelomonocytic leukemia patients [2].

KRAS is an inclusion eligibility criterion in 2 clinical trials for juvenile myelomonocytic leukemia, of which 1 is open and 1 is closed. Of the trials that contain KRAS status and juvenile myelomonocytic leukemia as inclusion criteria, 2 are phase 2 (1 open) [3].

MECOM is an inclusion eligibility criterion in 7 clinical trials for juvenile myelomonocytic leukemia, of which 3 are open and 4 are closed. Of the trials that contain MECOM status and juvenile myelomonocytic leukemia as inclusion criteria, 2 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (1 open), and 1 is phase 3 (1 open) [3].

MLLT1 is an inclusion eligibility criterion in 7 clinical trials for juvenile myelomonocytic leukemia, of which 3 are open and 4 are closed. Of the trials that contain MLLT1 status and juvenile myelomonocytic leukemia as inclusion criteria, 2 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (1 open), and 1 is phase 3 (1 open) [3].

MLLT10 is an inclusion eligibility criterion in 7 clinical trials for juvenile myelomonocytic leukemia, of which 3 are open and 4 are closed. Of the trials that contain MLLT10 status and juvenile myelomonocytic leukemia as inclusion criteria, 2 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (1 open), and 1 is phase 3 (1 open) [3].

MLLT3 is an inclusion eligibility criterion in 7 clinical trials for juvenile myelomonocytic leukemia, of which 3 are open and 4 are closed. Of the trials that contain MLLT3 status and juvenile myelomonocytic leukemia as inclusion criteria, 2 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (1 open), and 1 is phase 3 (1 open) [3].

MLLT4 is an inclusion eligibility criterion in 7 clinical trials for juvenile myelomonocytic leukemia, of which 3 are open and 4 are closed. Of the trials that contain MLLT4 status and juvenile myelomonocytic leukemia as inclusion criteria, 2 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (1 open), and 1 is phase 3 (1 open) [3].

MNX1 is an inclusion eligibility criterion in 1 clinical trial for juvenile myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains MNX1 status and juvenile myelomonocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

MYH11 is an inclusion eligibility criterion in 1 clinical trial for juvenile myelomonocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains MYH11 status and juvenile myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

NF1 is an inclusion eligibility criterion in 1 clinical trial for juvenile myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains NF1 status and juvenile myelomonocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

NRAS is altered in 9.09% of juvenile myelomonocytic leukemia patients [2].

NRAS is an inclusion eligibility criterion in 2 clinical trials for juvenile myelomonocytic leukemia, of which 1 is open and 1 is closed. Of the trials that contain NRAS status and juvenile myelomonocytic leukemia as inclusion criteria, 2 are phase 2 (1 open) [3].

NRIP3 is an inclusion eligibility criterion in 7 clinical trials for juvenile myelomonocytic leukemia, of which 3 are open and 4 are closed. Of the trials that contain NRIP3 status and juvenile myelomonocytic leukemia as inclusion criteria, 2 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (1 open), and 1 is phase 3 (1 open) [3].

NSD1 is an inclusion eligibility criterion in 1 clinical trial for juvenile myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains NSD1 status and juvenile myelomonocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

NUP214 is an inclusion eligibility criterion in 7 clinical trials for juvenile myelomonocytic leukemia, of which 3 are open and 4 are closed. Of the trials that contain NUP214 status and juvenile myelomonocytic leukemia as inclusion criteria, 2 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (1 open), and 1 is phase 3 (1 open) [3].

NUP98 is an inclusion eligibility criterion in 1 clinical trial for juvenile myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains NUP98 status and juvenile myelomonocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].

PBX1 is an inclusion eligibility criterion in 5 clinical trials for juvenile myelomonocytic leukemia, of which 3 are open and 2 are closed. Of the trials that contain PBX1 status and juvenile myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), and 1 is phase 3 (1 open) [3].

PTPN11 is an inclusion eligibility criterion in 2 clinical trials for juvenile myelomonocytic leukemia, of which 1 is open and 1 is closed. Of the trials that contain PTPN11 status and juvenile myelomonocytic leukemia as inclusion criteria, 2 are phase 2 (1 open) [3].

RPN1 is an inclusion eligibility criterion in 7 clinical trials for juvenile myelomonocytic leukemia, of which 3 are open and 4 are closed. Of the trials that contain RPN1 status and juvenile myelomonocytic leukemia as inclusion criteria, 2 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (1 open), and 1 is phase 3 (1 open) [3].

RUNX1 is an inclusion eligibility criterion in 2 clinical trials for juvenile myelomonocytic leukemia, of which 1 is open and 1 is closed. Of the trials that contain RUNX1 status and juvenile myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 2 (1 open) [3].

RUNX1T1 is an inclusion eligibility criterion in 1 clinical trial for juvenile myelomonocytic leukemia, of which 0 are open and 1 is closed. Of the trial that contains RUNX1T1 status and juvenile myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (0 open) [3].

TCF3 is an inclusion eligibility criterion in 5 clinical trials for juvenile myelomonocytic leukemia, of which 3 are open and 2 are closed. Of the trials that contain TCF3 status and juvenile myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 2 are phase 2 (1 open), and 1 is phase 3 (1 open) [3].

TP53 is an inclusion eligibility criterion in 7 clinical trials for juvenile myelomonocytic leukemia, of which 3 are open and 4 are closed. Of the trials that contain TP53 status and juvenile myelomonocytic leukemia as inclusion criteria, 2 are phase 1 (0 open), 1 is phase 1/phase 2 (1 open), 3 are phase 2 (1 open), and 1 is phase 3 (1 open) [3].

WT1 is an inclusion eligibility criterion in 1 clinical trial for juvenile myelomonocytic leukemia, of which 1 is open and 0 are closed. Of the trial that contains WT1 status and juvenile myelomonocytic leukemia as inclusion criteria, 1 is phase 2 (1 open) [3].